Summary: A 5-Year Registry study of Humira (adalimumab) in Subjects with moderately to severely active Crohn's Disease.

Inclusion Criteria:

- Subjects who are newly prescribed adalimumab
- Subjects who are participants in Abbott sponsored investigational Crohn's disease trials and are currently receiving adalimumab

Exclusion Criteria:

- Subjects should not be enrolled if they cannot be treated in accordance with the local product label

Contact:

Sheri Stottlemire, PCT, Assistant Clinical Research Coordinator
Telephone: 785-270-488
Email: sstottle@stormontvail.org